Why Did OrganiGram Holdings Fall 20% Yesterday?

What next for OrganiGram investors after stock falls 68% in the last year.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Another cannabis stock bites the dust after it reported preliminary quarterly earnings. Shares of OrganiGram Holdings (TSXV:OGI)(NASDAQ:OGI) fell close to 20% yesterday after the company announced its preliminary fiscal fourth quarter of 2019 (year ended in August).

In fiscal 2019, OGI estimates sales of $80.4 million, a rise of 547% year over year. The company has estimated net profit at $16.3 million. However, OGI expects lower sales in the fourth quarter and $1.6 million of packaging inventory adjustments in the August quarter to result in a negative adjusted EBITDA.

OGI expects to report improvement in the cost of cultivation per gram on a sequential basis as the harvested volume in yield per plant were normalized in the fourth quarter.

OGI CEO Greg Engel stated, “While Q4 2019 did not meet our overall expectations, we have not only emerged as one of the national leaders in the industry with significant growth expected in net revenue and strong market share, we expect to report positive adjusted EBITDA for the year.

He added, “And we remain relentlessly focused on running a profitable business which earns attractive returns on investment for our shareholders over the near and long term. We are encouraged by Ontario’s recent announcement to expand the retail network and believe this should be an important catalyst to drive further growth for us and the industry as a whole.”

Similar to other cannabis companies, OGI has also been impacted by the lack of a robust retail network and slower than expected store openings in key provinces such as Ontario.

OGI further stated that market share is an important indicator of success for licensed producers, and sell-through to the end consumer is also a solid predictor of long-term sustainable growth. OrganiGram has a sales network across 10 Canadian provinces.

Although OGI has not given the market share it occupies in the cannabis market, it claims to have an enviable share in Canada’s adult-use recreational space. OGI is one of the major players in Ontario and according to Ontario Cannabis Store; its OrganiGram’s Edison brand was among the top-three selling pre-rolls in the province.

A look at OGI’s expectations

OrganiGram satisfied with its liquidity and capital reserve to fund operations and complete the expansion of its Moncton campus. At the end of the August quarter, OGI’s cash and short-term investments will be close to $48 million while total debt will be $49.6 million.

In the first quarter of fiscal 2020, OGI has already shipped more sales compared to the same point in the August quarter. However, the company has refrained from providing guidance for the November quarter.

OrganiGram is on track to launch vape pens in mid-December, while cannabis-infused chocolate products will be launched in early 2020. While OGI and several other cannabis companies remain optimistic about long-term growth, there’s a certain amount of uncertainty in a highly regulated market struggling with oversupply and lower than expected demand.

OGI stock is currently trading at $3.57, which is 68% below its 52-week high. Analysts have an average target price of $8.24 for OGI which is 125% above the current trading pric at writing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends OrganiGram Holdings and OrganiGram Holdings. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »